Literature DB >> 12005399

Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma.

Shoichi Nagai1, Kazuo Washiyama, Masanori Kurimoto, Akira Takaku, Shunro Endo, Toshiro Kumanishi.   

Abstract

OBJECT: It has been suggested that nuclear factor (NF)-kappaB, a pleiotropic transcription factor, controls cell proliferation. The authors examined NF-kappaB activity and its participation in the growth of human malignant astrocytoma.
METHODS: The authors examined NF-kappaB activity in human malignant astrocytoma cell lines and high-grade astrocytoma tissues by using electrophoretic mobility shift assays and immunohistochemical studies, respectively. In addition, messenger (m)RNA expression of p50 and RelA, which are representative subunits of NF-kappaB, and IkappaBalpha, which is a representative inhibitory protein of NF-KB, were analyzed using Northern blot hybridization in the astrocytoma cell lines. Furthermore, alterations in DNA synthesis and cell growth in the astrocytoma cell lines were examined after inhibition of NF-kappaB activity by RelA antisense oligodeoxynucleotide. The authors found NF-kappaB activity in all astrocytoma cell lines and high-grade astrocytoma tissues that were examined, but not in the fetal astrocyte strain or in normal cerebral tissue. Expression of p50, RelA, and IkappaBalpha mRNA was found in the fetal astrocyte strain and normal adult brain tissue, in addition to the astrocytoma cell lines. The relative levels of expression of these mRNAs were similar among these cell lines, the cell strain, and normal tissue. The RelA antisense oligodeoxynucleotide specifically reduced the levels of RelA mRNA expression and NF-kappaB activity in the astrocytoma cell lines, thus significantly inhibiting their DNA synthesis and cell growth.
CONCLUSIONS: Human malignant astrocytoma cells have aberrant NF-KB activity, which promotes their growth. This activity is not associated with aberrant expression of p50 and RelA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12005399     DOI: 10.3171/jns.2002.96.5.0909

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  44 in total

1.  NFKBIA deletion in glioblastomas.

Authors:  Markus Bredel; Denise M Scholtens; Ajay K Yadav; Angel A Alvarez; Jaclyn J Renfrow; James P Chandler; Irene L Y Yu; Maria S Carro; Fangping Dai; Michael J Tagge; Roberto Ferrarese; Claudia Bredel; Heidi S Phillips; Paul J Lukac; Pierre A Robe; Astrid Weyerbrock; Hannes Vogel; Steven Dubner; Bret Mobley; Xiaolin He; Adrienne C Scheck; Branimir I Sikic; Kenneth D Aldape; Arnab Chakravarti; Griffith R Harsh
Journal:  N Engl J Med       Date:  2010-12-22       Impact factor: 91.245

Review 2.  The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas.

Authors:  Florence Lefranc; Robert Kiss
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

3.  Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.

Authors:  Pierre A Robe; Didier H Martin; Minh T Nguyen-Khac; Maria Artesi; Manuel Deprez; Adelin Albert; Sophie Vanbelle; Stephane Califice; Markus Bredel; Vincent Bours
Journal:  BMC Cancer       Date:  2009-10-19       Impact factor: 4.430

4.  PTEN enhances TNF-induced apoptosis through modulation of nuclear factor-kappaB signaling pathway in human glioma cells.

Authors:  Dimpy Koul; Yasunari Takada; Ruijun Shen; Bharat B Aggarwal; W K Alfred Yung
Journal:  Biochem Biophys Res Commun       Date:  2006-09-25       Impact factor: 3.575

5.  Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype.

Authors:  Baisakhi Raychaudhuri; Yulong Han; Tao Lu; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2007-05-04       Impact factor: 4.130

Review 6.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

7.  Promyelocytic leukemia protein induces apoptosis due to caspase-8 activation via the repression of NFkappaB activation in glioblastoma.

Authors:  Kazuyuki Kuwayama; Kazuhito Matsuzaki; Yoshihumi Mizobuchi; Hideo Mure; Keiko T Kitazato; Teruyoshi Kageji; Mitsuyoshi Nakao; Shinji Nagahiro
Journal:  Neuro Oncol       Date:  2008-09-23       Impact factor: 12.300

8.  NF-kappaB controls growth of glioblastomas/astrocytomas.

Authors:  Denise Smith; Takeshi Shimamura; Stephanie Barbera; Bruce E Bejcek
Journal:  Mol Cell Biochem       Date:  2007-09-09       Impact factor: 3.396

9.  A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.

Authors:  Toshimasa Akazawa; Shawn G Kwatra; Laura E Goldsmith; Mark D Richardson; Elizabeth A Cox; John H Sampson; Madan M Kwatra
Journal:  J Neurochem       Date:  2009-03-11       Impact factor: 5.372

10.  The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway.

Authors:  Asmaa Sina; Sébastien Proulx-Bonneau; Alain Roy; Laurent Poliquin; Jian Cao; Borhane Annabi
Journal:  J Cell Commun Signal       Date:  2010-01-27       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.